Straits Times Index
3,359.63 +21.06 (+0.63%) Nikkei
40,023.52 +392.46 (+0.99%) Hang Seng
17,783.97 +65.36 (+0.37%) FTSE 100
8,166.76 +2.64 (+0.03%) Bitcoin USD
62,973.12 -367.82 (-0.58%) CMC Crypto 200
1,346.26 +44.19 (+3.39%)
QURE Jul 2024 4.000 call
| Previous close | 1.0000 |
| Open | 0.9500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 4.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.9400 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%
Key Insights Given the large stake in the stock by institutions, uniQure's stock price might be vulnerable to their...
PR NewswireGenezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
Genezen, a best-in-class gene therapy CDMO, today announced an agreement to acquire uniQure's (Nasdaq: QURE) commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company. Under the terms of the agreement, Genezen will enter into strategic supply agreements for uniQure's clinical portfolio and CSL's commercial HEMGENIX® product, the first one-time gene therapy approved in the U.S. and Europe for the treatment o
GlobeNewswireuniQure Announces Sale of Commercial Manufacturing Facility to Genezen
~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~ ~ Genezen to manufacture global commercial supply of HEMGENIX® and support uniQure’s pipeline programs as a preferred customer ~ ~ uniQure to reduce cash burn by $40 million per year and receive total consideration of $25 million ~ ~ uniQure’s comprehensive review of operations and options to reduce expenses is ongoing and expected to be comp
